Ketamine is a highly effective, fast-acting antidepressant that works even for patients who have not responded to other medications. However, the brain mechanisms important for these rapid treatment ...

"Not only did the compound bind the 5-HT2A serotonin receptor like we thought it would, but it had the same anti-depressant drug action as does ketamine but not the same hallucinogenic drug action." ...

Ketamine may or may not be considered a psychedelic compound; it’s relatively subjective, just like the psychedelic realm itself. It all comes down to the intention, personal definitions, and ...

During 2010 41 new psychoactive substances were officially notified to the European Union, nearly double than during the previous year, most of which are available on Internet. One of these new ...

Currently, the ketamine treatment market is limited to intravenous (IV) or oral delivery. While effective, the cost of treatments like ketamine infusions can be between $400 and $2000 per infusion.

The patent applications refer to novel proprietary compositions of 3,4-methylenedioxymethamphetamine (MDMA), ibogaine, and ketamine, each combined with palmitoylethanolamide (“PEA”), the ...

Ketamine and psilocybin are currently Schedule I and Schedule III controlled substances, respectively, under the Controlled Drugs and Substances Act, S.C. 1996, c. 19 (the "CDSA") and it is a ...

Ketamine and psilocybin are currently Schedule I and Schedule III controlled substances, respectively, under the Controlled Drugs and Substances Act, S.C. 1996, c. 19 (the "CDSA") and it is a ...